Tichakunda Mharazanye: A New Year, New Challenges, And New Milestones
Tichakunda Mharazanye, Pharmacy student at RIMT University, shared on LinkedIn about a recent article he and his colleague co-authored, adding:
”A new year, new challenges, and new milestones
The start of this year came with its fair share of pressure, tight deadlines and moments of selfdoubt.
Staying consistent, focused and curious helped me push through and l am grateful to begin the year by sharing my latest review publication.
Our work explores hemophilia beyond clotting factors, focusing on albumin as an underappreciated prognostic and diagnostic marker.
The review highlights how albumin reflects disease burden, influences bleeding severity and joint outcomes, and plays a key role in the pharmacokinetics of modern hemophilia therapies opening doors for more personalized prophylaxis.
Grateful for the learning process, the resilience it builds, and the opportunity to contribute to advancing patient-centered care in hemophilia.”
Title: Hemophilia And Albumin: Quantitative Analysis For Prognostic And Diagnostic Applications
Authors: Tichakunda Xavier Mharazanye, Shaun Muponda
Read the Full Article on The International Journal of Engineering Development and Research
More winner stories featured in Hemostasis Today.
-
Jun 29, 2026, 15:50Sweta Agrawal: Expanding Care for PNH Patients in Nepal
-
Jun 29, 2026, 15:17Heghine Khachatryan: Hemostasis at the Crossroads of Thrombosis and Bleeding
-
Jun 29, 2026, 15:07Tomaz Crochemore: From Bleeding to Thrombosis – The Era of Precision Hemostatic Medicine Has Arrived
-
Jun 29, 2026, 14:51Pete Stibbs: Building a Successful Venous Thrombectomy Practice
-
Jun 29, 2026, 14:30Bruno Pougault: Pregnancy and Thrombosis – Balancing Evolutionary Protection Against Clinical Risk
-
Jun 29, 2026, 13:32Omid Seidizadeh: The Full VWD Session from EHA 2026 Is Now Available to Watch
-
Jun 29, 2026, 13:22Cheryl Carcel: Make The Stroke Research More Inclusive for Women, Take The Survey
-
Jun 29, 2026, 13:18Bianca Rocca: New Expert Opinion On the Evolving Debate on Factor XI as a Therapeutic Target
-
Jun 29, 2026, 13:06Francisco Chacón-Lozsán: Intermittent Hemodialysis in the ICU Should not be Monitored Only by ‘Session Completed’